| 摘要 |
The invention comprises 3-p-fluorophenylmethyl -6- chloro -7- sulphamoyl-3, 4-dihydrobenzo-1, 2, 4-thiadiazine-1, 1-dioxide and its preparation by reacting 5-chloro-2, 4-disulphamoyl-aniline with a b -p-fluorophenylethyl compound such as p-fluorophenylethyl alcohol and simultaneously oxidising, e.g. by boiling with chromic acid in an aqueous medium, to effect ring closure between the amino group and the nitrogen of the 2-sulphamoyl group by means of the a -carbon atom of the fluorophenylethyl compound. Reference has been directed by the Comptroller to Specification 861,367.ALSO:Pharmaceutical preparations having diuretic activity, for the treatment of cardiac, cardiorenal and renal oedemas, hypertension, ascitic cirrhoses, neurohormonal oedemas, obesity and angina pectoris, comprise the compound 3-p-fluorophenylmethyl - 7 - sulphamoyl - 6 - chloro-3,4 - dihydro - 1,2,4 - benzothiadiazene - 1,1-dioxide (see Division C2), together with an inert diluent or excipient, or with one or more Rauwolfia alkaloids and, optionally, an inert diluent or excipient. The preparations may be liquid or solid and are preferably administered orally. Examples describe tablets containing the benzothiadiazine compound with (a) an inert solid excipient, and (b) reserpine, rescinnamine, raupine, ajmaline, methyl yohimbate and an inert solid excipient. Reference has been directed by the Comptroller to Specification 861,367. |
